Advanced cell therapy; marketing MACI (cartilage repair) and Epicel (skin replacementt) in TAMs of $2b+. Q2 MACI and Epicel 2Q20 revs of $26.2m (vs $19m in 2018). 2019 revenue guidance for MACI® and Epicel® raised to $112 to $116m. Expanded MACI salesforce. Recently acquired US commercial rights for NexoBrid; BLA filing targeted for 1H 2020. .
Biotechnology, Medical Device, Medical Technology
500MM - 1B
64 Sidney Street
Cambridge, MA 02139
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Solebury Trout Management Access: SF 2020
San Francisco, CA, United States,
January 13 –
January 16, 2020
Stock Market Data
Market Data copyright © 2019 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by